Drugs for Gastrointestinal Diseases Practice Questions

Q: Esomeprazole acts by inhibiting which of the following?

H+K+ ATPase pump. **Explanation:** **Esomeprazole** is the S-isomer of omeprazole and belongs to the class of **Proton Pump Inhibitors (PPIs)**. 1. **Mechanism of Action (Why A is correct):** PPIs are prodrugs that require an acidic environment (canaliculus of the parietal cell) to be converted into their active form, the **sulfenamide**. This active form binds covalently via disulfide bonds to the **H+K+ ATPase enzyme** (the "proton pump") located on the apical membrane of gastric parietal cells. This inhibition is **irreversible**, leading to a potent and long-lasting suppression of gastric acid secretion (both basal and stimulated). 2. **Why other options are incorrect:** * **Option B (H+Na+ ATPase):** This pump does not exist in the gastric parietal cells for acid secretion. The primary exchange involves Hydrogen and Potassium ions. * **Option C (H+ pump):** While colloquially called a "proton pump," the specific physiological name of the enzyme is the H+K+ ATPase. In medical examinations, the specific ionic exchange mechanism is the preferred answer. * **Option D:** Since only the H+K+ ATPase is the target, this option is incorrect. **High-Yield Clinical Pearls for NEET-PG:** * **Administration:** PPIs should be taken **30–60 minutes before meals** (usually breakfast) because the number of H+K+ ATPase pumps on the canalicular surface is maximal after a period of fasting. * **Drug of Choice:** PPIs are the DOC for Peptic Ulcer Disease (PUD), GERD, and **Zollinger-Ellison Syndrome**. * **Side Effects:** Long-term use is associated with **Hypomagnesemia**, Vitamin B12 deficiency, and increased risk of *C. difficile* infections and osteoporotic fractures (due to decreased calcium absorption). * **Esomeprazole Advantage:** It has higher oral bioavailability and provides more sustained acid control compared to the racemic mixture (Omeprazole).

Q: Triple therapy for H. pylori includes all EXCEPT?

Sucralfate. **Explanation:** The standard **Triple Therapy** for *Helicobacter pylori* eradication is the first-line treatment regimen used to manage peptic ulcer disease and prevent recurrence. It typically consists of a Proton Pump Inhibitor (PPI) and two antibiotics. **Why Sucralfate is the correct answer:** Sucralfate is a mucosal protective agent that forms a physical barrier (paste) over the ulcer base. While it aids in ulcer healing, it has **no antimicrobial activity** against *H. pylori*. Therefore, it is not a component of the standard triple therapy regimen. **Analysis of Incorrect Options:** * **Omeprazole (Option A):** A PPI is a core component of triple therapy. It increases gastric pH, which not only promotes healing but also enhances the stability and efficacy of the co-administered antibiotics. * **Clarithromycin (Option B):** This is a macrolide antibiotic and the most potent agent against *H. pylori* in the regimen. * **Metronidazole (Option C):** This is an imidazole antibiotic often used as an alternative to Amoxicillin in patients with penicillin allergy, or as part of the standard triple therapy in certain geographical regions. **NEET-PG High-Yield Pearls:** 1. **Standard Triple Therapy (OCM/OCA):** Omeprazole + Clarithromycin + Metronidazole (or Amoxicillin) for 10–14 days. 2. **Bismuth Quadruple Therapy:** Used if triple therapy fails or in areas of high clarithromycin resistance. It includes **PPI + Bismuth subsalicylate + Metronidazole + Tetracycline**. 3. **Pylera:** A 3-in-1 capsule containing Bismuth, Metronidazole, and Tetracycline. 4. **Sequential Therapy:** 5 days of PPI + Amoxicillin, followed by 5 days of PPI + Clarithromycin + Tinidazole.

Q: What is true about Octreotide?

Is used in secretory diarrhea. **Explanation:** **Octreotide** is a synthetic octapeptide and a potent long-acting **somatostatin analogue** [1]. It mimics the natural hormone somatostatin but has a much longer half-life (approx. 1.5 hours vs. 2 minutes) [3]. **Why Option C is Correct:** Octreotide is highly effective in treating **secretory diarrhea** associated with carcinoid tumors, VIPomas, and HIV/AIDS [3]. It works by inhibiting the secretion of various gastrointestinal hormones (like serotonin, gastrin, and VIP) and reducing intestinal fluid and electrolyte secretion [5]. It also slows gastrointestinal motility and reduces splanchnic blood flow [3]. **Analysis of Incorrect Options:** * **Option A:** Octreotide is a peptide; it is degraded by gastric enzymes and is **not active orally**. It must be administered parenterally (Subcutaneous or Intravenous) [5]. * **Option B:** It **is** a somatostatin analogue, specifically targeting somatostatin receptors (SSTR-2 and SSTR-5) [4]. * **Option D:** It is a **growth hormone antagonist** (inhibitor). It is used clinically to treat acromegaly by suppressing the release of Growth Hormone (GH) from the pituitary gland [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Variceal Bleeding:** Octreotide is a first-line drug for acute variceal hemorrhage because it causes splanchnic vasoconstriction, thereby reducing portal pressure [5]. * **Dumping Syndrome:** Used to manage symptoms post-gastrectomy. * **Side Effects:** The most common side effects are biliary sludge and **gallstones** (due to inhibition of cholecystokinin and gallbladder contractility) and steatorrhea [2].

Q: Which of the following is a 5-HT3 antagonist?

Ondansetron. ### Explanation **Correct Answer: D. Ondansetron** **Mechanism of Action:** Ondansetron is a selective **5-HT3 receptor antagonist** [1]. These receptors are located peripherally on vagal nerve terminals in the gastrointestinal tract and centrally in the **Chemoreceptor Trigger Zone (CTZ)** and the Nucleus Tractus Solitarius (NTS) [1], [2]. By blocking these receptors, Ondansetron inhibits the initiation of the vomiting reflex, making it highly effective for preventing chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV) [1], [2]. **Analysis of Incorrect Options:** * **A. Levocetirizine:** This is a second-generation **H1-receptor antagonist** used primarily for allergic rhinitis and urticaria [2]. It has no significant effect on 5-HT3 receptors. * **B. Metoclopramide:** While it has weak 5-HT3 antagonistic properties at high doses, its primary mechanism is as a **D2-receptor antagonist** [3]. It also acts as a 5-HT4 agonist, which contributes to its prokinetic effect. * **C. Domperidone:** This is a peripheral **D2-receptor antagonist** [3]. Unlike metoclopramide, it does not cross the blood-brain barrier easily, resulting in fewer extrapyramidal side effects. **NEET-PG High-Yield Pearls:** * **Drug of Choice:** 5-HT3 antagonists (the "-setrons") are the drugs of choice for **Chemotherapy-Induced Nausea and Vomiting (CINV)** [1]. * **Side Effects:** The most common side effects are **headache** and constipation. A critical ECG finding to remember is **QT interval prolongation**. * **Palonosetron:** This is a second-generation 5-HT3 antagonist with a longer half-life, often used for delayed emesis [1], [3]. * **Site of Action:** They act both at the peripheral (visceral afferents) and central (CTZ) levels [1].

Q: What is true about lactulose?

Is an osmotic laxative. ### Explanation **Correct Answer: C. Is an osmotic laxative** Lactulose is a synthetic disaccharide consisting of **galactose and fructose**. It is not absorbed in the small intestine because humans lack the specific enzyme to hydrolyze it. Upon reaching the colon, resident bacteria (like *Bifidobacterium* and *Lactobacillus*) ferment it into low-molecular-weight organic acids (lactic, acetic, and formic acids). These acids increase the osmotic pressure in the lumen, drawing water into the bowel, softening the stool, and stimulating peristalsis. Thus, it acts as a classic **osmotic laxative**. **Analysis of Incorrect Options:** * **A. Increases blood ammonia:** Incorrect. Lactulose is actually used to **decrease** blood ammonia in Hepatic Encephalopathy. The organic acids produced lower the colonic pH (acidification), which converts diffusible ammonia ($NH_3$) into non-diffusible ammonium ions ($NH_4^+$). This "ion trapping" prevents ammonia absorption into the blood. * **B. Is 10% absorbed from the gut:** Incorrect. Lactulose is essentially **non-absorbable** (<3% absorption). Its therapeutic efficacy depends entirely on its presence in the colonic lumen. * **D. Is a disaccharide of lactose and sucrose:** Incorrect. It is a disaccharide composed of **galactose and fructose**. **High-Yield Clinical Pearls for NEET-PG:** * **Hepatic Encephalopathy:** Lactulose is the first-line treatment. It works via two mechanisms: **ion trapping** ($NH_3 \rightarrow NH_4^+$) and changing gut flora to non-urease-producing bacteria. * **Side Effects:** Flatulence and abdominal cramps are common due to gas production during fermentation. * **Other Osmotic Laxatives:** Magnesium hydroxide (Milk of Magnesia), Polyethylene Glycol (PEG), and Sorbitol.

Q: Which of the following drugs is NOT indicated in drug-induced vomiting?

Hyoscine. **Explanation:** The management of vomiting depends on the specific receptors involved in the triggering pathway. Drug-induced vomiting (caused by chemotherapy, opioids, or general anesthetics) primarily triggers the **Chemoreceptor Trigger Zone (CTZ)** located in the area postrema. The CTZ is rich in **Dopamine (D2)**, **Serotonin (5-HT3)**, and **Neurokinin (NK1)** receptors. **Why Hyoscine is the Correct Answer:** Hyoscine (Scopolamine) is an anticholinergic drug that acts on **M1 receptors** in the vestibular apparatus and the vomiting center. It is the drug of choice for **motion sickness**, but it has no significant effect on the CTZ. Therefore, it is ineffective and **not indicated** for drug-induced or metabolic causes of vomiting. **Analysis of Incorrect Options:** * **Metoclopramide:** A D2 receptor antagonist that acts centrally on the CTZ and peripherally as a prokinetic. It is commonly used for drug-induced emesis (except cisplatin-induced). * **Ondansetron:** A potent 5-HT3 receptor antagonist. It is the gold standard for preventing chemotherapy-induced and post-operative nausea and vomiting (PONV). * **Chlorpromazine:** A broad-spectrum antiemetic (neuroleptics group) that blocks D2 receptors in the CTZ. It is effective against most drug-induced and systemic causes of vomiting. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of choice for Motion Sickness:** Hyoscine (transdermal patch is most effective). * **Drug of choice for Morning Sickness:** Doxylamine + Pyridoxine. * **Drug of choice for Cisplatin-induced vomiting:** Ondansetron (often combined with Dexamethasone or Aprepitant). * **Vomiting Center vs. CTZ:** The CTZ is outside the blood-brain barrier (BBB), making it easily accessible to circulating drugs and toxins.

Q: Which of the following is useful to decrease mortality and renal failure in acute liver disease due to alcoholism?

Pentoxifylline. **Explanation:** **Pentoxifylline** is the correct answer because it is a non-selective phosphodiesterase inhibitor that reduces the production of **Tumor Necrosis Factor-alpha (TNF-α)**. In severe alcoholic hepatitis, TNF-α is a key mediator of systemic inflammation and hepatocyte injury. Clinical trials have demonstrated that Pentoxifylline significantly reduces the risk of **hepatorenal syndrome (HRS)**, thereby decreasing mortality in patients with severe acute alcoholic hepatitis, especially when corticosteroids are contraindicated. **Analysis of Incorrect Options:** * **Orlistat:** A gastric and pancreatic lipase inhibitor used for weight loss. It prevents the absorption of dietary fats and has no role in acute liver failure or mortality reduction in alcoholic hepatitis. * **S-Adenosyl methionine (SAMe):** A precursor to glutathione. While it has been studied for chronic liver disease to improve antioxidant status, it has not shown a definitive mortality benefit in acute alcoholic liver disease. * **Syrlamysin (Silymarin):** An extract from milk thistle used as a "hepatoprotective" agent. While it has antioxidant properties, it lacks robust clinical evidence for reducing mortality or preventing renal failure in acute alcoholic hepatitis. **High-Yield Clinical Pearls for NEET-PG:** * **Maddrey Discriminant Function (MDF):** A score >32 indicates severe alcoholic hepatitis where treatment is required. * **First-line Treatment:** Prednisolone is generally the first-line treatment for severe alcoholic hepatitis. * **Pentoxifylline Indication:** Used as an alternative to steroids or when steroids are contraindicated (e.g., active infection, GI bleed) specifically to prevent renal failure. * **Mechanism:** Pentoxifylline improves microcirculation by increasing erythrocyte flexibility and decreasing blood viscosity.

Q: Which of the following drugs effectively treats ulcers by inhibiting gastric acid secretion?

Ranitidine. The correct answer is **Ranitidine**. To understand why, we must categorize drugs used in peptic ulcer disease based on their mechanism of action: those that **reduce acid secretion**, those that **neutralize acid**, and those that **protect the mucosa** [2]. **Why Ranitidine is correct:** Ranitidine is a competitive **H₂-receptor antagonist**. It works by blocking the histamine H₂ receptors on the basolateral membrane of gastric parietal cells. This inhibition leads to a significant reduction in both basal and meal-stimulated gastric acid secretion [1]. **Analysis of Incorrect Options:** * **Lactulose (A):** This is an osmotic laxative and an ammonia-detoxifying agent used in chronic constipation and hepatic encephalopathy. It has no role in acid inhibition. * **Aluminium hydroxide (B):** This is an **antacid**. While it treats ulcers, it does so by **neutralizing** existing gastric acid (increasing pH) rather than inhibiting its secretion. * **Sucralfate (C):** This is a **mucosal protective agent**. In an acidic environment (pH < 4), it polymerizes into a sticky paste that binds to the ulcer base, creating a physical barrier against acid and pepsin. It does not inhibit acid production. **High-Yield Clinical Pearls for NEET-PG:** * **Potency:** Proton Pump Inhibitors (PPIs) like Omeprazole are more potent than H₂ blockers because they inhibit the "final common pathway" (H+/K+ ATPase pump) [1, 2]. * **Side Effects:** Cimetidine (another H₂ blocker) is notorious for causing **gynecomastia** and inhibiting Cytochrome P450 enzymes; Ranitidine has a much lower affinity for these. * **Tolerance:** Unlike PPIs, H₂ blockers can exhibit **tachyphylaxis** (rapidly diminishing response) within a few days of use.

Q: Which of the following drugs inhibits the release of acetylcholine from cholinergic nerves in the submucosa and myenteric complex?

Loperamide. **Explanation:** **Loperamide** is a synthetic opioid agonist that acts primarily on the **$\mu$-opioid receptors** located in the myenteric plexus of the intestinal wall. When these receptors are activated, they inhibit the release of **acetylcholine** and prostaglandins. Since acetylcholine is the primary excitatory neurotransmitter responsible for intestinal propulsive motility, its inhibition leads to decreased peristalsis and increased intestinal transit time. This allows for greater water absorption, making it an effective anti-diarrheal agent. Unlike morphine, loperamide does not cross the blood-brain barrier in therapeutic doses, thus lacking central analgesic effects. **Analysis of Incorrect Options:** * **Pectin (A):** This is a dietary fiber (bulk-forming agent) that works by absorbing water and adding bulk to the stool. It does not interfere with neurotransmitter release. * **Docusate (B):** This is a stool softener (anionic surfactant). it works by lowering the surface tension of the stool, allowing water and lipids to penetrate the fecal mass. * **Cholestyramine (D):** This is a bile acid sequestrant. It is used to treat diarrhea specifically caused by bile acid malabsorption (e.g., post-ileal resection) by binding bile salts in the lumen. **NEET-PG High-Yield Pearls:** * **Mechanism:** Loperamide = $\mu$-receptor agonist $\rightarrow$ $\downarrow$ Acetylcholine $\rightarrow$ $\downarrow$ Motility. * **Contraindication:** Avoid in infectious diarrhea (e.g., *Shigella*, *Salmonella*) as slowing motility can delay the clearance of toxins and lead to **Toxic Megacolon**. * **Comparison:** Unlike Diphenoxylate (another opioid anti-diarrheal), Loperamide has negligible abuse potential and does not require co-administration with Atropine.

Question 1

Esomeprazole acts by inhibiting which of the following?

Accepted Answer

H+K+ ATPase pump

Answer

H+Na+ ATPase pump

Answer

H+ pump

Answer

Any of the above

Question 2

Triple therapy for H. pylori includes all EXCEPT?

Accepted Answer

Sucralfate

Answer

Omeprazole

Answer

Clarithromycin

Answer

Metronidazole

Question 3

What is true about Octreotide?

Accepted Answer

Is used in secretory diarrhea

Answer

Is active orally

Answer

Is not a somatostatin analogue

Answer

Is a growth hormone agonist

Question 4

Which of the following is a 5-HT3 antagonist?

Accepted Answer

Ondansetron

Answer

Levocetirizine

Answer

Metoclopromide

Answer

Domperidone

Question 5

What is true about lactulose?

Accepted Answer

Is an osmotic laxative

Answer

Increases blood ammonia

Answer

Is 10% absorbed from the gut

Answer

Is a disaccharide of lactose and sucrose

Question 6

Which of the following drugs is NOT indicated in drug-induced vomiting?

Accepted Answer

Hyoscine

Answer

Metoclopramide

Answer

Ondansetron

Answer

Chlorpromazine

Question 7

Which sulfonamide is useful in treating ulcerative colitis?

Accepted Answer

Sulfasalazine

Answer

Sulfadiazine

Answer

Sulfamethoxazole

Answer

Sulfadimidine

Question 8

Which of the following is useful to decrease mortality and renal failure in acute liver disease due to alcoholism?

Accepted Answer

Pentoxifylline

Answer

Orlistat

Answer

S-Adenosyl methionine

Answer

Syrlamysin

Question 9

Which of the following drugs effectively treats ulcers by inhibiting gastric acid secretion?

Accepted Answer

Ranitidine

Answer

Lactulose

Answer

Aluminium hydroxide

Answer

Sucralfate

Question 10

Which of the following drugs inhibits the release of acetylcholine from cholinergic nerves in the submucosa and myenteric complex?

Accepted Answer

Loperamide

Answer

Pectin

Answer

Docusate

Answer

Cholestyramine

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?